VEGF (vascular endothelial growth factor) signaling and angiogenic approaches represent a compelling therapeutic strategy for Alzheimer's disease by targeting the neurovascular unit dysfunction that underlies disease progression. In AD, cerebral blood flow (CBF) reductions precede cognitive symptoms by years, and VEGF pathway impairment contributes to both vascular and neuronal pathology.
This category page covers companies developing:
The field builds on evidence that VEGF acts as a neurotrophic factor for hippocampal and cortical neurons, not merely an angiogenic cytokine. VEGF receptor 2 (VEGFR2/KDR) is expressed on neurons, and its activation promotes PI3K/Akt and MAPK/ERK survival signaling while simultaneously supporting vascular health[1][2].
Athira Pharma (NASDAQ: ATHA) is developing fosgonimeton (ATH-1017), a small molecule HGF/MET receptor activator with downstream neurotrophic and angiogenic effects relevant to AD.
| Attribute | Details |
|---|---|
| Focus | HGF/MET activation → neurovascular enhancement |
| Lead Candidate | Fosgonimeton (ATH-1017) |
| Indication | Alzheimer's disease |
| Stage | Phase 2/3 (ACT-AD study) |
| Mechanism | HGF/MET receptor agonist |
Scientific Rationale: The HGF/MET system shares downstream signaling with VEGF pathways (PI3K/Akt, MAPK/ERK) and promotes angiogenesis, neuroprotection, and improved cerebral blood flow. Activation of MET receptors on both neurons and endothelial cells provides dual neurovascular benefit[3].
Clinical Development:
Key Advantages: Small molecule oral drug, addresses both neurotrophic and vascular components of AD, disease-modifying potential.
4D Molecular Therapeutics (NASDAQ: FDMT) is developing 4D-150, a dual VEGF/brain-derived neurotrophic factor (BDNF) vector using its proprietary R100 capsid for intravitreal delivery, with applications extending to CNS angiogenic modulation[3:1].
| Attribute | Details |
|---|---|
| Focus | VEGF/BDNF co-expression gene therapy |
| Platform | R100 capsid (intravitreal delivery) |
| Indication | Wet AMD, with CNS applications in development |
| Stage | Phase 2 (eye); CNS preclinical |
Notes: While 4D-150 is primarily developed for wet age-related macular degeneration (wet AMD), the company's VEGF/BDNF combination approach has potential AD applications through local CNS delivery strategies. The R100 capsid enables high-efficiency gene delivery to neural tissues.
Roche and Genentech have explored VEGF pathway modulation in AD through anti-amyloid approaches with indirect neurovascular effects:
| Attribute | Details |
|---|---|
| Focus | Anti-Aβ antibodies with neurovascular benefit |
| Lead Candidates | Gantenerumab, Crenezumab |
| Indication | Alzheimer's disease |
| Stage | Phase 3 (DIAN-TU, SKYPOOL) |
| Mechanism | Aβ plaque reduction → reduced CAA → improved CBF |
Scientific Rationale: By clearing amyloid plaques and vascular amyloid (CAA), anti-Aβ antibodies reduce the amyloid burden on cerebral vessels, potentially restoring cerebral blood flow. Gantenerumab in particular has shown dose-dependent CAA reduction in the SCarlet Roads trial[4].
Asahi Kasei, a Japanese conglomerate, has research programs in VEGF receptor modulation for CNS applications:
| Attribute | Details |
|---|---|
| Focus | VEGFR modulators for neurodegeneration |
| Stage | Discovery |
| Region | Japan |
| Notes | Research collaboration with academic institutions |
Takeda maintains broad neurodegeneration research programs including neurovascular restoration approaches:
| Attribute | Details |
|---|---|
| Focus | Neurovascular unit restoration |
| Stage | Discovery/preclinical |
| Notes | Broad CNS portfolio includes angiogenic research |
Cerevance is developing CVN231, a compound targeting neural circuit stabilization with neurovascular effects:
| Attribute | Details |
|---|---|
| Focus | Neural circuit and neurovascular enhancement |
| Platform | Nuclear receptor modulation |
| Indication | Alzheimer's disease, Parkinson's disease |
| Stage | Preclinical |
| Company | Mechanism | Stage | Notes |
|---|---|---|---|
| AbbVie | VEGF pathway modulators | Discovery | Broad neurodegeneration research |
| Biocon | VEGF biosimilar programs | Preclinical | Indian biotech, CNS focus |
| Dompé | Neurotrophin analogs | Research | Italian biotech, neurotrophic focus |
| Cellectricon | VEGF screening platform | Research | Contract research for VEGF pathway |
| Oryzon Genomics | Epigenetic modulators (LSD1) with angiogenic effects | Phase 1 | CNS indications |
Direct activation of VEGF signaling for dual neurovascular benefit:
| Target | Approach | Companies |
|---|---|---|
| VEGFR2 activation | VEGFR2 agonists, VEGF mimetics | Asahi Kasei (research) |
| VEGF expression | Gene therapy, AAV delivery | 4DMT (exploratory) |
| VEGFR downstream | HGF/MET activators (shared pathway) | Athira Pharma |
| VEGF-B signaling | VEGFR1/Flt1 modulation | Research |
Direct approaches to restore cerebral perfusion:
| Target | Approach | Companies |
|---|---|---|
| Neurovascular coupling | NO signaling modulators | Multiple programs |
| Endothelial function | LRP1 activators | Research |
| Vasodilation | PDE inhibitors, NO donors | Research |
| Microvascular density | Angiogenic growth factors | Research |
| Pericyte function | PDGF-BB agonists | Preclinical |
Promoting new blood vessel formation in the brain:
| Target | Approach | Companies |
|---|---|---|
| Angiogenic signaling | VEGF, FGF, HGF delivery | Multiple programs |
| Endothelial progenitor cells | Cell therapy approaches | Research |
| Angiogenic switch | HIF prolyl hydroxylase inhibitors | Research |
| VEGF isoform optimization | VEGF-Axxx/bxxx modulation | Research |
Comprehensive targeting of the neurovascular unit:
| Target | Approach | Companies |
|---|---|---|
| Neurovascular coupling | Neural-vascular signaling modulators | Cerevance |
| BBB restoration | Tight junction enhancers | Research |
| Pericyte coverage | PDGF-BB signaling | Preclinical |
| Astrocyte function | AQP4 polarization | Research |
Reduced cerebral blood flow is an early and progressive feature of AD:
Beyond its canonical angiogenic role, VEGF acts as a neurotrophic factor for hippocampal and cortical neurons[1:1][6]:
The coupling between angiogenesis and neuroprotection enables dual benefits:
Multiple studies document VEGF pathway alterations in AD brains[7][8]:
Angiogenesis is impaired in AD through multiple mechanisms:
VEGF-based approaches address AD through multiple mechanisms:
| Company | Drug | Phase | Indication | Status |
|---|---|---|---|---|
| Athira Pharma | Fosgonimeton (ATH-1017) | Phase 2/3 | AD (ACT-AD) | Recruiting |
| Roche | Gantenerumab | Phase 3 | AD (DIAN-TU) | Ongoing |
| Roche | Crenezumab | Phase 2 | AD (ABBV explorers) | Completed |
| 4DMT | 4D-150 | Phase 2 | Wet AMD (eye); CNS exploratory | Active |
| Biocon | VEGF programs | Preclinical | AD | Discovery |
| Takeda | NVU restoration | Discovery | AD | Discovery |
The main challenge with VEGF-based therapies is balancing angiogenic benefits against risks:
| Risk | Mitigation Strategy |
|---|---|
| Tumor angiogenesis | Selective VEGFR2 targeting, CNS-specific delivery |
| Vascular permeability | Using non-permeabilizing VEGF isoforms or mimetic peptides |
| Hemorrhage | Careful dose titration, avoiding existing CAA |
| Hypotension | Local delivery or BBB-penetrating small molecules |
| Off-target angiogenesis | Tissue-specific delivery, regulated expression |
VEGF therapies may synergize with other AD approaches:
VEGF in the central nervous system: function and dysfunction. Nature Reviews Neuroscience. 2023. ↩︎ ↩︎
VEGF and neurodegeneration: mechanisms and therapeutic potential. Brain Research. 2024. ↩︎
Neurotrophic factors in Alzheimer's disease. Nature Reviews Neuroscience. 2023. ↩︎ ↩︎
Cerebral amyloid angiopathy and VEGF signaling. Acta Neuropathologica. 2022. ↩︎
Cerebral blood flow reduction in Alzheimer's disease. Lancet Neurology. 2023. ↩︎
Non-angiogenic functions of VEGF in the brain. Progress in Neurobiology. 2022. ↩︎
VEGF alterations in Alzheimer's disease brain. Journal of Alzheimer's Disease. 2022. ↩︎
VEGF-based therapeutic approaches for Alzheimer's disease. Alzheimer's Research & Therapy. 2022. ↩︎